David W. Carley
Hoofd Techniek/Wetenschap/O&O bij Pier Pharmaceuticals, Inc.
Profiel
David W.
Carley is currently the Director & Chief Scientific Officer at Pier Pharmaceuticals, Inc. and a Professor at the University of Illinois.
He was formerly a Director at RespireRx Pharmaceuticals, Inc. Carley received a doctorate degree from Harvard University in 1985, a doctorate degree from Massachusetts Institute of Technology, and a graduate degree from Massachusetts Institute of Technology in 1982.
Actieve functies van David W. Carley
| Bedrijven | Functie | Begin |
|---|---|---|
Pier Pharmaceuticals, Inc.
 Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Pier Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company which develops a pharmacologic treatment for obstructive sleep apnea (OSA). It develops Dronabinol a synthetic derivative of the naturally occurring substance in the cannabis plant, namely delta-9-tetrahydrocannabinol, otherwise known as delta-9 THC. The company was founded in 2007 and is headquartered in Louiseville, CO. | Hoofd Techniek/Wetenschap/O&O | 29-06-2011 |
| University of Illinois | Corporate Officer/Principal | 29-06-2011 |
Eerdere bekende functies van David W. Carley
| Bedrijven | Functie | Einde |
|---|---|---|
| RESPIRERX PHARMACEUTICALS INC. | Directeur/Bestuurslid | - |
Opleiding van David W. Carley
| Harvard University | Doctorate Degree |
| Massachusetts Institute of Technology | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| RESPIRERX PHARMACEUTICALS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Pier Pharmaceuticals, Inc.
Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Pier Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company which develops a pharmacologic treatment for obstructive sleep apnea (OSA). It develops Dronabinol a synthetic derivative of the naturally occurring substance in the cannabis plant, namely delta-9-tetrahydrocannabinol, otherwise known as delta-9 THC. The company was founded in 2007 and is headquartered in Louiseville, CO. | Health Technology |
